Easier and more accessible testing for SARS-CoV-2 (COVID-19)
Ubiquitome has partnered with The SalivaDirect Initiative at Yale School of Public Health to enhance public access to COVID-19 testing, with United States Food and Drug Administration (FDA) emergency use authorization (EUA) of the combination of SalivaDirect™ with Ubiquitome’s Liberty16 mobile real time-PCR.
In Yale School of Public Health testing the Liberty16 displayed performance similar to large, lab-bound instruments.
|Proteinase K||Primer/Probe||RT-qPCR kit||RT-qPCR instrument||LOD||Positive replicates||Mean Ct value (SD)|
|Thermo||IDT||NEB Luna (2x)||Agilent AriaMX||6 copies/μL||100% (20/20)||30.3 (0.4)|
|Thermo||Eurofins||NEB Luna (2x)||Liberty16||12 copies/μL||100% (20/20)||35.18 (0.7)|
|Thermo||IDT||NEB Luna (2x)||CFX384 Touch||6 copies/μL||100% (20/20)||36.25 (0.4)|
Ubiquitome gets FDA authorization with Yale SARS-CoV-2 self-collection tests19 December, 2022
NIH RADx winner’s next gen Liberty16 Pro gets EUA Auckland, December 19, 2022: Ubiquitome’s next generation real time PC...
Ubiquitome’s Liberty16 Pro ready to carve up next COVID wave27 July, 2022
Faster mobile PCR test device helping business continuity Chicago, July 27, 2022: Ubiquitome , which won through the Uni...
Ubiquitome Ltd. is ISO 13485 certified6 September, 2021
As of 31st August 2021, Ubiquitome Ltd. is ISO 13485:2016 certified for its Quality Management System through BSI Group....
"Costly instruments for real-time PCR analysis often stand in the way of equitable access for under resourced communities and countries and sustainability of testing systems"
Ubiquitome’s world class team is changing how the world accesses and shares genomic information.About us